KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $201.2 million.

  • Amneal Pharmaceuticals' Cash & Equivalents rose 171.94% to $201.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.2 million, marking a year-over-year increase of 171.94%. This contributed to the annual value of $110.6 million for FY2024, which is 20.77% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Cash & Equivalents of $201.2 million as of Q3 2025, which was up 181.29% from $71.5 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Cash & Equivalents high stood at $452.1 million for Q1 2021, and its period low was $26.0 million during Q4 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $86.9 million (2023), whereas its average is $94.5 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first slumped by 89.52% in 2022, then surged by 252.41% in 2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash & Equivalents (Quarterly) stood at $247.8 million in 2021, then crashed by 89.52% to $26.0 million in 2022, then spiked by 252.41% to $91.5 million in 2023, then rose by 20.77% to $110.6 million in 2024, then surged by 171.94% to $201.2 million in 2025.
  • Its Cash & Equivalents was $201.2 million in Q3 2025, compared to $71.5 million in Q2 2025 and $59.2 million in Q1 2025.